Halozyme Therapeutics: Event Overview and Recent Share Performance

Halozyme Therapeutics (HALO) has recently drawn investor attention without a single headline event driving sentiment. This shifts focus squarely onto its share performance and fundamentals for context.

The stock closed at US$69.57, with a 0.4% move over the past day, about 3.9% over the past week, and roughly 9.7% over the past month, while the past 3 months show a 1.2% decline.

That recent upswing in the share price sits alongside a 1-year total shareholder return of 21.43% and a 3-year total shareholder return of 107.42%. The year to date share price return is slightly negative, suggesting longer term momentum remains stronger than the short term picture.

If you are comparing Halozyme with other potential ideas in healthcare and biotech, this is a good moment to see what else is moving through 35 healthcare AI stocks

So with a 21.43% 1 year total return, annual revenue and net income growth, and the share price sitting below the average analyst target, are you looking at an underappreciated opportunity or a stock where future growth is already priced in?

Most Popular Narrative: 18% Undervalued

Halozyme's most followed valuation narrative points to a fair value of about $84.89 per share versus the last close at $69.57, putting the current price at a clear discount in that framework.

The accelerating adoption of subcutaneous drug delivery in place of traditional intravenous administration, evidenced by rapid conversion rates (e.g., DARZALEX subcutaneous now 96% in the US) and label expansions (Phesgo for at-home administration), positions Halozyme's ENHANZE platform as a core beneficiary of the global shift towards more patient-friendly, convenient, and cost-effective treatment modalities. This structural shift is expected to support continued robust growth in royalty revenues and net margin expansion over the long term.

Curious what sits behind that valuation gap? The narrative leans on a specific blend of double digit revenue growth assumptions, sharply higher margins, and a future earnings multiple that is lower than many comparable biotech names. The exact mix of those inputs is what drives the $84.89 figure.

Result: Fair Value of $84.89 (UNDERVALUED)

However, this depends on key assumptions, and issues such as concentrated royalty exposure and ongoing patent challenges could quickly change sentiment around that 18% discount story.

Another Angle: Market Multiple Sends a Different Signal

The narrative fair value of about $84.89 suggests Halozyme looks undervalued, but the current P/E of 26x tells a different story. It sits above the US Biotechs average of 17.1x, above peers at 20.3x, and above a fair ratio of 18.5x. This points to valuation risk if sentiment cools.

For anyone weighing these mixed signals, this higher P/E versus both peers and the fair ratio raises a simple question: is the premium a cushion for long term growth or a margin of safety that has already been spent?

Next Steps

Mixed signals on value and growth can be confusing. Check the full picture for yourself and weigh both sides by reviewing the 3 key rewards and 4 important warning signs.

Looking for more investment ideas?

If Halozyme has caught your eye, do not stop here. Use this momentum to broaden your watchlist with other opportunities that fit different roles in a portfolio.

• Target potential mispriced opportunities and see which companies stand out on quality and value using the 63 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with robust payouts through the 13 dividend fortresses.
• Prioritise downside protection and check out companies with steadier risk profiles via the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.